Here's a recap of recent blog posts and other news.
RxISK's petitions to the FDA and EMA about the permanent sexual side effects resulting from antidepressants appear to be under active consideration. We have written to all affected asking them if they are willing to let us indicate to the regulator they are prepared to put their names forward. The rationale here is that regulators often dismiss hundreds of reports on the basis that, without names, these are hearsay. It is not possible to dismiss the reports of people willing to be questioned in the same way, especially those whose doctors also indicate they see no other way to explain the problem; the justice system could not function if witness testimony could be dismissed in this manner.
Allied to this, RxISK has now submitted a petition to the FDA asking that PRSD (Post Retinoid Sexual Dysfunction) be included on the label of retinoid drugs prescribedfor acne (see Petition for Isotretinoin Sexual Side Effects).
On DavidHealy.org, recent posts have centred on a major crisis in Evidence Based Medicine linked to a dispute between Peter Goetzsche and the Cochrane Collaboration. Goetzsche and his supporters see no point in continuing the charade of reviewing ghostwritten publications without access to the underlying data.
Thank you for your support.
Your feedback, as always, is greatly appreciated.
David Healy, MD